Tedizolid
- Generic Name
- Tedizolid
- Brand Names
- Sivextro
- Drug Type
- Small Molecule
- Chemical Formula
- C17H15FN6O3
- CAS Number
- 856866-72-3
- Unique Ingredient Identifier
- 97HLQ82NGL
- Background
Drug-resistant bacteria, such as methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and penicillin-resistant Streptococcus penumoniae, represent a massive public health threat. Tedizolid is a member of the oxazolidinone class of antibiotics, which includes the previously approved linezolid and is generally effective against multidrug-resistant Gram-positive bacteria. Tedizolid is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and is generally more effective and more tolerable than linezolid.
Tedizolid was approved by the FDA on June 20, 2014, for sale by Cubist Pharmaceuticals as tedizolid phosphate (SIVEXTRO®). This product is currently available as both an oral tablet and as a powder for intravenous injection.
- Indication
用于特定的敏感细菌引起的成人急性细菌性皮肤和皮肤结构感染（ABSSSI）。抗菌谱为金黄色葡萄球菌(包括耐甲氧西林和甲氧西林敏感菌株)，化脓性链球菌，无乳链球菌，咽峡炎链球菌群(包括咽峡炎链球菌、中间型链球菌、星群链球菌)，粪肠球菌。
- Associated Conditions
- Acute Bacterial Skin and Skin Structure Infection (ABSSSI)
A Study to Evaluate Oral Formulations of Tedizolid Phosphate in Healthy Participants (MK-1986-043)
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2024-12-13
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 36
- Registration Number
- NCT06733688
- Locations
- 🇺🇸
Celerion (Site 0001), Lincoln, Nebraska, United States
A Study to Compare Oral Formulations of Tedizolid Phosphate in Healthy Adults (MK-1986-044)
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2024-09-24
- Last Posted Date
- 2024-09-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 18
- Registration Number
- NCT06609161
- Locations
- 🇺🇸
Celerion (Site 0001), Lincoln, Nebraska, United States
Evaluation of the Early Bactericidal Activity of Tedizolid and Linezolide Against Mycobacterium Tuberculosis (TEDITUB)
- Conditions
- TuberculosisMultidrug Resistant Tuberculosis
- Interventions
- First Posted Date
- 2022-09-09
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 60
- Registration Number
- NCT05534750
- Locations
- 🇫🇷
Bacteriology department- Hôpital Saint-Antoine, Paris, France
Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis
- Conditions
- Endocarditis Infective
- Interventions
- Drug: Fusidic Acid Only Product in Oral Dose FormDrug: Fusidic Acid Only Product in Parenteral Dose Form
- First Posted Date
- 2022-06-01
- Last Posted Date
- 2025-03-11
- Lead Sponsor
- Fundacion Clinic per a la Recerca Biomédica
- Target Recruit Count
- 360
- Registration Number
- NCT05398679
- Locations
- 🇪🇸
Hospital Virgen de la Macarena, Sevilla, Andalucía, Spain
🇪🇸Hospital Virgen del Rocío, Sevilla, Andalucía, Spain
🇪🇸Parc Taulí Hospital Universitari, Sabadell, Barcelona, Spain
Efficacy and Tolerance of 4 Weeks of Tedizolid in Prosthetic Joint Infections Treated With Implant Removal
- Conditions
- Prostheses Infection
- Interventions
- First Posted Date
- 2018-11-19
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- Fundacion Clinic per a la Recerca Biomédica
- Target Recruit Count
- 30
- Registration Number
- NCT03746327
- Locations
- 🇪🇸
Laura Morata, Barcelona, Spain
Tedizolid Prolonged Treatment for Prosthetic Joint Infections
- Conditions
- Prosthetic Joint Infection
- Interventions
- First Posted Date
- 2017-12-19
- Last Posted Date
- 2021-09-08
- Lead Sponsor
- Tourcoing Hospital
- Target Recruit Count
- 35
- Registration Number
- NCT03378427
- Locations
- 🇫🇷
Hôpital Ambroise Paré, Boulogne-Billancourt, France
🇫🇷Hôpital de la Croix Rousse, Lyon, France
A Pharmacokinetic Study of Tedizolid Phosphate in Pediatric Participants With Gram-Positive Infections (MK-1986-014)
- Conditions
- Gram-Positive Infections
- Interventions
- First Posted Date
- 2017-07-14
- Last Posted Date
- 2025-02-11
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 47
- Registration Number
- NCT03217565
- Locations
- 🇧🇬
MHAT Rousse-Neonatology ( Site 2213), Ruse, Bulgaria
🇧🇬Multiprofile Hospital for Active Treatment - Ruse ( Site 2204), Ruse, Bulgaria
🇺🇸Arkansas Children's Hospital ( Site 1012), Little Rock, Arkansas, United States
A Study of Safety and Efficacy of MK-1986 (Tedizolid Phosphate) and Comparator in Participants From Birth to Less Than 12 Years of Age With Acute Bacterial Skin and Skin Structure Infections (MK-1986-018)
- Conditions
- Acute Bacterial Skin and Skin Structure Infections
- Interventions
- Drug: Comparator
- First Posted Date
- 2017-06-05
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 100
- Registration Number
- NCT03176134
- Locations
- 🇺🇸
Ann & Robert H. Lurie Children's Hospital of Chicago ( Site 0129), Chicago, Illinois, United States
🇧🇷Inst de Medicina Integral Professor Fernando Figueira- IMIP ( Site 0277), Recife, Pernambuco, Brazil
🇧🇬UMHAT Deva Maria ( Site 0333), Burgas, Bulgaria
Tolerability, Safety, and Efficacy of Tedizolid as Oral Treatment for Bone and Joint Infections (OTTER)
- First Posted Date
- 2017-01-04
- Last Posted Date
- 2023-12-13
- Target Recruit Count
- 44
- Registration Number
- NCT03009045
- Locations
- 🇺🇸
Harbor-UCLA Medical Center, Torrance, California, United States
🇺🇸Los Angeles BioMedical Research Institute (LA BioMed), Torrance, California, United States
Sivextro in Acute Bacterial Skin and Skin Structure Infection (ABSSSI) in Hospitalized Patients. A Global Observational Study
- Conditions
- Skin Disease, Infectious
- Interventions
- First Posted Date
- 2016-12-13
- Last Posted Date
- 2019-10-02
- Lead Sponsor
- Bayer
- Target Recruit Count
- 108
- Registration Number
- NCT02991131
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.